Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.50 |
| ▸ | PGR | P06401 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893565 | 0.80 | ALDH1A1 (0.76) | CYP19A1ALDH1A1SMN1; SMN2TSHRHTT | |
| SCHEMBL2006618 | 0.78 | NR3C1 (0.51) | ALDH1A1SMN1; SMN2NR3C1PGRLMNA | |
| SCHEMBL30596341 | 0.75 | SMN1; SMN2 (0.59) | CYP19A1ALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL29087314 | 0.75 | SMN1; SMN2 (0.59) | CYP19A1ALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL2004236 | 0.74 | NR3C1 (0.59) | ALDH1A1SMN1; SMN2NR3C1PGRLMNA | |
| SCHEMBL28003775 | 0.73 | SMN1; SMN2 (0.74) | CYP19A1ALDH1A1SMN1; SMN2TSHRHTT | |
| SCHEMBL13537713 | 0.73 | ALDH1A1 (0.72) | CYP19A1ALDH1A1SMN1; SMN2TSHRHTT | |
| SCHEMBL2009285 | 0.73 | NR3C1 (0.52) | CYP19A1ALDH1A1SMN1; SMN2NR3C1PGR | |
| SCHEMBL2002824 | 0.72 | GAA (0.47) | ALDH1A1SMN1; SMN2HTTNR3C1PGR | |
| SCHEMBL28195553 | 0.72 | HTT (0.75) | CYP19A1ALDH1A1SMN1; SMN2HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | CYP19A1 304/4885ALDH1A1 1050/4885SMN1; SMN2 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.